These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11922863)

  • 1. Pharmaceutical thrombosis prevention in cardiovascular disease.
    Eriksson M; Christensen K; Lindahl TL; Larsson A
    Expert Opin Investig Drugs; 2002 Apr; 11(4):553-63. PubMed ID: 11922863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New perspectives in antiplatelet therapy.
    Tello-Montoliu A; Jover E; Rivera J; Valdés M; Angiolillo DJ; Marín F
    Curr Med Chem; 2012; 19(3):406-27. PubMed ID: 22335515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet therapy in acute coronary syndromes.
    Aragam KG; Bhatt DL
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
    Cook JJ; Sitko GR; Holahan MA; Stranieri MT; Glass JD; Askew BC; McIntyre CJ; Claremon DA; Baldwin JJ; Hartman GD; Gould RJ; Lynch JJ
    J Pharmacol Exp Ther; 1997 May; 281(2):677-89. PubMed ID: 9152373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute and long-term antiplatelet therapy.
    Papathanasiou AI; Goudevenos JA; Mikhailidis DP; Tselepis AD
    Drugs Today (Barc); 2008 May; 44(5):331-52. PubMed ID: 18548136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological control of platelet function.
    Clutton P; Folts JD; Freedman JE
    Pharmacol Res; 2001 Oct; 44(4):255-64. PubMed ID: 11592859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future.
    De Luca G; Savonitto S; van't Hof AW; Suryapranata H
    Drugs; 2015 Jul; 75(11):1229-53. PubMed ID: 26177890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
    Vorchheimer DA; Badimon JJ; Fuster V
    JAMA; 1999 Apr; 281(15):1407-14. PubMed ID: 10217057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continued thromboxane A2 formation despite administration of a platelet glycoprotein IIb/IIIa antagonist in patients undergoing coronary angioplasty.
    Byrne A; Moran N; Maher M; Walsh N; Crean P; Fitzgerald DJ
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3224-9. PubMed ID: 9409315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa and P2Y12 receptor antagonists yield additive inhibition of platelet aggregation, granule secretion, soluble CD40L release and procoagulant responses.
    Judge HM; Buckland RJ; Holgate CE; Storey RF
    Platelets; 2005 Nov; 16(7):398-407. PubMed ID: 16236601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral antiplatelet, antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa antagonist.
    Mousa SA; DeGrado WF; Mu DX; Kapil RP; Lucchesi BR; Reilly TM
    Circulation; 1996 Feb; 93(3):537-43. PubMed ID: 8565173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapies: platelet GPIIb/IIIa antagonists and beyond.
    Mousa SA
    Curr Pharm Des; 2003; 9(28):2317-22. PubMed ID: 14529393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa receptor antagonists: clinical pharmacology in cardiovascular diseases of aging.
    Sebastian M; Makkar R
    Drugs Aging; 1999 Sep; 15(3):207-18. PubMed ID: 10503813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of roxifiban (DMP754), a novel oral platelet glycoprotein IIb/IIIa receptor inhibitor, in patients with stable coronary artery disease.
    Murphy J; Wright RS; Gussak I; Williams B; Daly RN; Cain VA; Pieniaszek HJ; Sy SK; Ebling W; Simonson K; Wilcox RA; Kopecky SL
    Am J Cardiovasc Drugs; 2003; 3(2):101-12. PubMed ID: 14727937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.
    Liu F; Craft RM; Morris SA; Carroll RC
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2673-87. PubMed ID: 11060829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa inhibitors in percutaneous coronary intervention: focus on the pharmacokinetic-pharmacodynamic relationships of eptifibatide.
    Gilchrist IC
    Clin Pharmacokinet; 2003; 42(8):703-20. PubMed ID: 12846593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of microsurgical thrombosis by the platelet glycoprotein IIb/IIIa antagonist SR121566A.
    Ching S; Thoma A; Monkman S; Kelton JG
    Plast Reconstr Surg; 2003 Jul; 112(1):177-85. PubMed ID: 12832891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPIIb/IIIa inhibitors: from bench to bedside and back to bench again.
    Armstrong PC; Peter K
    Thromb Haemost; 2012 May; 107(5):808-14. PubMed ID: 22370973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet Glycoprotein IIb/IIIa receptor blockade with oral xemilofiban: results of a multicenter, placebo-controlled, randomized trial.
    Kereiakes DJ; Kleiman NS; Ferguson JJ; Masud AR; Broderick TM; Abbottsmith CW; Runyon JP; Anderson LC; Anders RJ; Dreiling RJ; Hantsbarger GL; Bryzinski B; Topol EJ
    Circulation; 1998 Sep; 98(13):1268-78. PubMed ID: 9751674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].
    Kala P; Poloczek M; Bocek O; Jerábek P; Neugebauer P; Kosová J; Semrád B
    Vnitr Lek; 2002 Aug; 48(8):736-41. PubMed ID: 12425204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.